文献速递帕金森病与运动障碍

左旋多巴在多巴反应性肌张力障碍中的现代观点

l-Dopa in dystonia: A modern perspective.
PubMed 文献 · Neurology · 2017-04-07

本文回顾了「每个肌张力障碍儿童都应尝试左旋多巴」这一源自1980年代的格言,讨论了左旋多巴在当前神经科实践中的诊断和治疗应用,并与获批适应症进行对比。作者认为,鉴于多巴反应性肌张力障碍(DRD)患病率低、所需剂量个体差异大、试验持续时间不确定以及病因和病理生理知识进展和先进诊断测试的可用性,对早发性肌张力障碍(≤25岁)将诊断性左旋多巴试验作为第一步已过时;在高资源国家,建议在生化证实多巴胺生物合成缺陷、基因确诊DRD或核成像显示黑质纹状体变性(成人下肢肌张力障碍)后使用左旋多巴。文献研究还显示左旋多巴偶尔对若干已确定的「非DRD」肌张力障碍有益,可考虑用于特定病例。

要点

  • 早发性肌张力障碍(≤25岁)不应常规将诊断性左旋多巴试验作为第一步。
  • 高资源国家建议在生化或基因确诊DRD或影像显示黑质纹状体变性后使用左旋多巴。
  • 左旋多巴对部分非DRD肌张力障碍病例可能有效,可考虑用于特定情况。

核心结论

  • 反对对每个早发性肌张力障碍患者使用左旋多巴,支持更合理的治疗使用。

研究设计与样本

  • 本文为综述,提供历史视角并讨论当前诊断和治疗应用。

主要发现

  • DRD患病率相对较低,左旋多巴所需剂量个体间差异大,试验持续时间不确定。
  • 病因和病理生理知识已有实质性进展,多种先进诊断测试可用。
  • 文献研究显示左旋多巴偶尔对若干已确定的「非DRD」肌张力障碍有益。

关键数值与推荐

  • 早发性肌张力障碍定义为≤25岁。
  • 建议在生化证实多巴胺生物合成缺陷、基因确诊DRD或核成像显示黑质纹状体变性(成人下肢肌张力障碍)后使用左旋多巴。

临床怎么用

  • 在高资源国家,对早发性肌张力障碍不应将诊断性左旋多巴试验作为第一步。
  • 根据生化、基因或影像证据选择患者使用左旋多巴。
  • 对部分非DRD肌张力障碍病例可考虑左旋多巴治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

"Every child exhibiting dystonia merits an l-dopa trial, lest the potentially treatable condition of dopa-responsive dystonia (DRD) is missed" has been a commonly cited and highly conserved adage in movement disorders literature stemming from the 1980s. We here provide a historical perspective on this statement, discuss the current diagnostic and therapeutic applications of l-dopa in everyday neurologic practice, contrast these with its approved indications, and finish with our view on both a diagnostic and therapeutic trial in children and adults with dystonia. In light of the relatively low prevalence of DRDs, the large interindividual variation in the required l-dopa dose, the uncertainty about an adequate trial duration, the substantial advances in knowledge on etiology and pathophysiology of these disorders, and the availability of various state-of-the-art diagnostic tests, we think that a diagnostic l-dopa trial as a first step in the approach of early-onset dystonia (≤25 years) is outdated. Rather, in high-resource countries, we suggest to use l-dopa after biochemical corroboration of a defect in dopamine biosynthesis, in genetically confirmed DRD, or if nigrostriatal degeneration has been demonstrated by nuclear imaging in adult patients presenting with lower limb dystonia. Furthermore, our literature study on the effect of a therapeutic trial to gain symptomatic relief revealed that l-dopa has occasionally proven beneficial in several established "non-DRDs" and may therefore be considered in selected cases of dystonia due to other causes. In summary, we argue against the application of l-dopa in every patient with early-onset dystonia and support a more rational therapeutic use.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Maas RPPWM, Wassenberg T, Lin JP, et al. l-Dopa in dystonia: A modern perspective. Neurology. 2017. PMID: 28389587. doi:10.1212/WNL.0000000000003897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。